11.65  -0.4 (-3.32%)		03-09 16:00
Open: 11.91 High: 12.305 Volume: 46,220		Pre. Close: 12.05 Low: 11.48 Market Cap: 15(M)

Short term
Mid term
Targets	6-month :	14.45	1-year :	15.64
Resists	First :	12.37	Second :	13.39
Pivot price	11.77
Supports	First :	10.72	Second :	8.92
MAs	MA(5) :	12.15	MA(20) :	11.64
	MA(100) :	7.98	MA(250) :	6.58
MACD	MACD :	0.5	Signal :	0.6
%K %D	K(14,3) :	45.1	D(3) :	53.3
RSI	RSI(14): 54.2
52-week	High :	13.39	Low :	4.52

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MSLE ] has closed above bottom band by 44.4%. Bollinger Bands are 19.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	12.51 - 12.57	12.57 - 12.63
Low:	11.7 - 11.77	11.77 - 11.84
Close:	11.91 - 12.03	12.03 - 12.15

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Tue, 10 Feb 2026
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares - BioSpace

Tue, 10 Feb 2026
Mintz Advises Satellos Bioscience in Its US$57.2 Million Initial US Public Offering - Mintz

Fri, 06 Feb 2026
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States - Business Wire

Thu, 05 Feb 2026
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq - Business Wire

Wed, 28 Jan 2026
Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing - Business Wire

Wed, 17 May 2023
MSCLF - Satellos Bioscience Inc Latest Stock News & Market Updates - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Shares Out	21 (M)
Shares Float	14 (M)
Held by Insiders	6.1 (%)
Held by Institutions	6.1 (%)
Shares Short	7 (K)
Shares Short P.Month	0 (K)

EPS	2.56
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.2
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-54.3 %
Return on Equity (ttm)	-87.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.81
Sales Per Share	0
EBITDA (p.s.)	-1.17
Qtrly Earnings Growth	0 %
Operating Cash Flow	-21 (M)
Levered Free Cash Flow	-14 (M)

PE Ratio	4.53
PEG Ratio	0
Price to Book value	5.29
Price to Sales	0
Price to Cash Flow	-11.33

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.